Healthcare strategy where regulatory context determines everything.

The GCC healthcare market is being reshaped by Vision 2030 health system transformation across Saudi Arabia, combined with Abu Dhabi's ambition to become a regional medical hub. Government health entities are upgrading procurement processes, bringing in private sector operators, and investing in health technology at a pace not seen before.

In India, the pharma sector is navigating post-pandemic supply chain reconfiguration, pricing pressure, and a regulatory environment that is tightening for both domestic and export markets. Global pharma companies with India manufacturing partnerships are reassessing their exposure.

We've done portfolio intelligence work for Abbott and GSK in this market – research that required 60+ KOL interviews across therapeutic areas. We know how to navigate the regulatory landscape and who to talk to.